Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark - internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, USA, and Genmab K.K. in Tokyo, Japan. It's a dual listed company with shares traded on the Copenhagen Stock Exchange in Denmark, and on NASDAQ Global Select Market in the US.
The company has 5 approved antibodies used in 7 marketed products, covering cancer indications and autoimmune diseases:
Proprietary, marketed with Seagen:
Marketed by partners:
Furthermore both Genmab and the partners have a whole range of antibody programs, building on Genmab technologies, in clinical and pre-clinical development. Genmab have several late stage clinical programs for tisotumab vedotin and epcoritamab. The partners have, among others, clinical programs for daratumumab, amivantamab, and teprotumumab.
Highest paying job titles at Genmab A/S include Medical Director, Clinical Research Scientist, and Director, Clinical Pharmacology